Laurence Labayen
Acute Care · Las Cruces, NMNPI 1588081822
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 41.5% of the total. Reporting peaked in 2021 at $200 and has fallen 87.6% since, to $25 in 2025.
Across 19 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$144
- Johnson & Johnson$122
- Baxter Healthcare$25
- Novo Nordisk$22
- Novartis$18
- AstraZeneca$16
What the payments were for
- Food & beverage$346100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 9 | $144 |
| Johnson & Johnson | 6 | $122 |
| Baxter Healthcare | 1 | $25 |
| Novo Nordisk | 1 | $22 |
| Novartis | 1 | $18 |
| AstraZeneca | 1 | $16 |
How this compares
$346 in reported general payments places this provider in the 60th percentile of 132 acute care providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 25 | $13,622 |
| Cefdinir | 25 | $447 |
| Atorvastatin Calcium | 19 | $255 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 24 | $218 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 32 | $169 |
| Doxycycline Hyclate | 12 | $161 |
| ClopidogrelClopidogrel Bisulfate | 16 | $141 |
| Pantoprazole Sodium | 16 | $131 |
| Prednisone | 23 | $98 |
| Metoprolol Succinate | 12 | $77 |
| Amlodipine Besylate | 14 | $74 |
| Lisinopril | 11 | $61 |
| Furosemide | 20 | $44 |
| Tramadol Hcl | 12 | $13 |
Paid to pharmacies, not to this prescriber.
Other acute care in Las Cruces
- Bernadette HerreraLas Cruces$6K
- Susann RavessoudLas Cruces$5K
- Viridiana ArellanoLas Cruces$3K
- Elicia CurrierLas Cruces$3K
- Mary YoungerLas Cruces$2K
- Danielle RuizLas Cruces$2K
- Edward CollinsLas Cruces$2K
- Tonee GonzalezLas Cruces$1K
- Taylor MartinezLas Cruces$1K
- Matthew FrancoLas Cruces$724
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.